Michael D. Pak

Array ( [id] => 11943308 [patent_doc_number] => 20170247459 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-31 [patent_title] => 'COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/288431 [patent_app_country] => US [patent_app_date] => 2016-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 51406 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15288431 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14883567 [patent_doc_number] => 10421810 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-09-24 [patent_title] => Chimeric antigen receptors and methods of use [patent_app_type] => utility [patent_app_number] => 15/767076 [patent_app_country] => US [patent_app_date] => 2016-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 29998 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15767076 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17364392 [patent_doc_number] => 11231410 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-01-25 [patent_title] => Method for identifying a compound useful in mitigating and/or the treatment of a disease associated with abnormal astrocytic function [patent_app_type] => utility [patent_app_number] => 15/766020 [patent_app_country] => US [patent_app_date] => 2016-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 6930 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 133 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15766020 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11650625 [patent_doc_number] => 20170146526 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-25 [patent_title] => 'COMPOSITIONS, KITS AND METHODS FOR IN VITRO ANTIGEN PRESENTATION, ASSESSING VACCINE EFFICACY, AND ASSESSING IMMUNOTOXICITY OF BIOLOGICS AND DRUGS' [patent_app_type] => utility [patent_app_number] => 15/286131 [patent_app_country] => US [patent_app_date] => 2016-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 23300 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15286131 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11542846 [patent_doc_number] => 20170096672 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-06 [patent_title] => 'Novel Ecdysone Receptor/Invertebrate Retinoid X Receptor-Based Inducible Gene Expression System' [patent_app_type] => utility [patent_app_number] => 15/285195 [patent_app_country] => US [patent_app_date] => 2016-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 27623 [patent_no_of_claims] => 41 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15285195 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11568620 [patent_doc_number] => 20170107265 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-20 [patent_title] => 'MET E 1 TROPOMYOSIN VARIANTS FOR USE IN ALLERGEN-SPECIFIC IMMUNOTHERAPY' [patent_app_type] => utility [patent_app_number] => 15/284205 [patent_app_country] => US [patent_app_date] => 2016-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 15274 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15284205 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13481739 [patent_doc_number] => 20180292412 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-11 [patent_title] => GDF-15 AS A DIAGNOSTIC MARKER TO PREDICT THE CLINICAL OUTCOME OF A TREATMENT WITH IMMUNE CHECKPOINT BLOCKERS [patent_app_type] => utility [patent_app_number] => 15/765174 [patent_app_country] => US [patent_app_date] => 2016-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25406 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15765174 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17921635 [patent_doc_number] => 11464856 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-11 [patent_title] => Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockers [patent_app_type] => utility [patent_app_number] => 15/765176 [patent_app_country] => US [patent_app_date] => 2016-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 22 [patent_no_of_words] => 28475 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15765176 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18153113 [patent_doc_number] => 11566074 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-31 [patent_title] => Antibody for immunoassay and method for preparing same [patent_app_type] => utility [patent_app_number] => 15/764041 [patent_app_country] => US [patent_app_date] => 2016-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 8022 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15764041 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11527257 [patent_doc_number] => 20170087234 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-30 [patent_title] => 'VACCINATION WITH IMMUNO-ISOLATED CELLS PRODUCING AN IMMUNOMODULATOR' [patent_app_type] => utility [patent_app_number] => 15/276016 [patent_app_country] => US [patent_app_date] => 2016-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 17979 [patent_no_of_claims] => 64 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15276016 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13533795 [patent_doc_number] => 20180318440 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-08 [patent_title] => MONOCLONAL ANTIBODIES SPECIFIC FOR FIBROBLAST GROWTH FACTOR RECEPTOR 4 (FGFR4) AND METHODS OF THEIR USE [patent_app_type] => utility [patent_app_number] => 15/761398 [patent_app_country] => US [patent_app_date] => 2016-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25837 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15761398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11493733 [patent_doc_number] => 20170067918 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-09 [patent_title] => 'COMPOSITION AND METHOD FOR MEASURING THALLIUM INFLUX AND EFFLUX' [patent_app_type] => utility [patent_app_number] => 15/269326 [patent_app_country] => US [patent_app_date] => 2016-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 12017 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15269326 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14662629 [patent_doc_number] => 10369191 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-08-06 [patent_title] => Modulation of epigenetic stress response [patent_app_type] => utility [patent_app_number] => 15/268079 [patent_app_country] => US [patent_app_date] => 2016-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 10741 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15268079 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14662629 [patent_doc_number] => 10369191 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-08-06 [patent_title] => Modulation of epigenetic stress response [patent_app_type] => utility [patent_app_number] => 15/268079 [patent_app_country] => US [patent_app_date] => 2016-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 10741 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15268079 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11542646 [patent_doc_number] => 20170096471 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-06 [patent_title] => 'SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR TREATMENT OF MEDICAL DISORDERS' [patent_app_type] => utility [patent_app_number] => 15/260171 [patent_app_country] => US [patent_app_date] => 2016-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11377 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15260171 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11419936 [patent_doc_number] => 20170028080 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-02 [patent_title] => 'Targeted Drug Conjugates' [patent_app_type] => utility [patent_app_number] => 15/227796 [patent_app_country] => US [patent_app_date] => 2016-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 12153 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15227796 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14820979 [patent_doc_number] => 10407481 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-09-10 [patent_title] => Ligands modified by circular permutation as agonists and antagonists [patent_app_type] => utility [patent_app_number] => 15/218193 [patent_app_country] => US [patent_app_date] => 2016-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 20 [patent_no_of_words] => 17390 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15218193 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16650013 [patent_doc_number] => 10927176 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-23 [patent_title] => Tumor-specific anti-EGFR antibody and application thereof [patent_app_type] => utility [patent_app_number] => 15/746711 [patent_app_country] => US [patent_app_date] => 2016-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 10 [patent_no_of_words] => 15905 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 633 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15746711 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13548497 [patent_doc_number] => 20180325796 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-15 [patent_title] => FUNCTIONAL REGULATORY ANTIBODY HAVING ACTIONS OF PROMOTING PROLIFERATION, SURVIVAL, AND CELL ACTIVATION OF DERMAL PAPILLA CELLS AS HAIR GROWTH REGULATING CENTER CELLS AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/775784 [patent_app_country] => US [patent_app_date] => 2016-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9066 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15775784 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16105627 [patent_doc_number] => 10695398 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-30 [patent_title] => Method of treating prostate cancer with GnRH antagonist [patent_app_type] => utility [patent_app_number] => 15/205108 [patent_app_country] => US [patent_app_date] => 2016-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 12 [patent_no_of_words] => 22299 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15205108 [rel_patent_id] =>[rel_patent_doc_number] =>)